Search

everythinglearnresearchcommunity

for

Search:↓

Adding antihistamines to topical corticosteroid and cryotherapy may improve hair regrowth in alopecia areata patients.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Urtica laetevirens extract significantly reduces 5α-reductase activity.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Upadacitinib effectively treats psoriasis and lichen planus together.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Ritlecitinib is effective long-term for treating alopecia areata in teens.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Both fluoxetine and clomipramine effectively treat dog lick dermatitis, but fluoxetine works faster with lower recurrence, while clomipramine has fewer side effects.

Topical cetirizine improves hair density and thickness in androgenetic alopecia, but more research is needed.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.